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Abstract
Introduction: Increased rates of cardiovascular disease are implicated in several rheumatologic diseases. Our aim
was to characterize dermatomyositis hospitalizations and evaluate cardiovascular-associated mortality in this patient
population.
Methods: We examined the frequency and mortality rates of several atherosclerotic cardiovascular diagnoses and
procedures among hospitalized adult patients with dermatomyositis using data from the US Nationwide Inpatient
Sample (NIS) from 1993 to 2007. We compared the odds of death among hospitalized dermatomyositis patients
with each cardiovascular diagnosis or procedure to those without, as well as to controls with cardiovascular
diagnoses, using logistic regression.
Results: A total of 50,322 hospitalizations of dermatomyositis patients occurred between 1993 and 2007 (mean
age 58 years, and 73% female). Of all dermatomyositis hospitalizations, 20% were associated with a concurrent
atherosclerotic cardiovascular diagnosis or procedure. The overall in-hospital mortality was 5.7%. Dermatomyositis
patients with any associated atherosclerotic cardiovascular diagnosis or procedure were twice as likely to die
during the inpatient stay compared to dermatomyositis patients who did not have atherosclerotic cardiovascular
disease (OR = 2.0 95% CI 1.7-2.5, p < 0.0001). The odds ratio for death in patients with both dermatomyositis and
cardiovascular disease compared to controls with cardiovascular disease alone was 1.98 (95% CI 1.57-2.48) in
multivariate adjusted models.
Conclusions: Approximately one fifth of dermatomyositis hospitalizations in the US were associated with an
atherosclerotic cardiovascular diagnosis or procedure. These patients have double the risk of in-hospital death in
comparison with controls and dermatomyositis patients without a cardiovascular diagnosis, making identification of
these groups important for both prognostic purposes and clinical care.
Introduction
Ischemic heart disease is more prevalent in rheumatolo-
gic diseases such as systemic lupus erythematosus and
rheumatoid arthritis [1-3] than in the general popula-
tion. Accelerated atherosclerosis in these populations is
thought to be related to the associated inflammatory
state, increased prevalence of cardiovascular risk factors,
and side effects of therapies such as corticosteroids [4].
Dermatomyositis is a rare autoimmune disease charac-
terized by symmetric proximal muscle weakness and an
associated cutaneous eruption. To date, it is not clear
whether atherosclerotic cardiovascular disease (CVD) is
more prevalent in patients with dermatomyositis com-
pared with the general population. Cardiac manifesta-
tions in patients with dermatomyositis include
congestive heart failure, arrhythmias, myocardial fibrosis,
and myocardial infarction (MI) [5]. Prior studies have
estimated that approximately 15% to 55% of deaths in
patients with dermatomyositis are due to CVD [6-8]. A
recent study in a South Australian population showed
that the prevalence of atherosclerotic risk factors,
including hypertension and diabetes, is significantly
higher in patients with inflammatory myopathies [9]
than in the general population. This Australian study
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included only 43 patients with dermatomyositis and had
missing data on more than half of these patients. In a
Canadian cohort, the incidence of acute MI was found
to be almost twice as high in patients with dermatomyo-
sitis or polymyositis compared with age- and gender-
matched controls without an inflammatory myositis, but
there was no estimation of prevalence or associated
mortality risk [10].
The burden of CVD in hospitalized patients with der-
matomyositis has not been described to date. The aims
of this analysis were to describe dermatomyositis hospi-
talizations in the US and to assess cardiovascular-related
mortality in a representative sample of US inpatients.
Materials and methods
Data
This is a case-control analysis of the Healthcare Cost
and Utilization Project Nationwide Inpatient Sample
(NIS) for the period of 1993 to 2007. The NIS is com-
posed of a stratified sample from 20% of US community
hospitals and contains about 7 million hospital discharge
records per year. Data from discharge summaries are
abstracted into the database for each individual hospita-
lization. The variables collected for each hospitalization
are age, gender, type of hospitalization (elective versus
non-elective), discharge diagnosis (primary and up to 14
secondary), procedures performed during the hospitali-
zation, and in-hospital mortality. As we used data that
are available to the public, the institutional review board
at Stanford University considered the study exempt
from review.
Inclusion and exclusion criteria
We identified all hospitalizations for patients who were at
least 18 years old and who had an International Classifica-
tion of Disease-9 Clinical Modification (ICD-9) for derma-
tomyositis (710.3) as either the primary or any of the
secondary diagnoses. To increase the specificity for a diag-
nosis of dermatomyositis, we excluded hospitalizations in
which there was a concurrent rheumatologic diagnosis of
polymyositis (710.4), systemic sclerosis (701.1), systemic
lupus erythematosus (710.0), or rheumatoid arthritis
(714.0). We also excluded hospitalizations for childbirth.
Validation of ICD-9 codes
In a previous study by our group, the ICD-9 code of 710.3
was validated against detailed medical record review and
was found to be adequately valid for a probable diagnosis
of dermatomyositis according to Bohan and Peter criteria
with a positive predictive value of 70% [11].
Atherosclerotic cardiovascular disease
Among this group, those with a concomitant discharge
diagnosis of acute or chronic CVDs or cardiovascular
procedures were identified. These included coronary
artery disease and acute MI (410.0 to 410.9, 412),
unstable angina (411.1, 411.81, 411.89), angina pectoris
(413, 413.1, 413.9), cardiac catheterization (372.1 to
372.3), percutaneous transluminal coronary angioplasty
(360.1 to 360.9), coronary artery bypass grafting (361.0
to 361.9), and congestive heart failure (428.0 to 428.9).
Comparison group
The control group consisted of age- and gender-
matched hospitalizations from the general discharge
population (10 per case) during the same time period as
dermatomyositis admissions. The control group did not
include diagnoses of rheumatologic diseases specified in
the exclusion criteria.
Statistical analyses
We compared the prevalence of cardiovascular diag-
noses or procedures as well as in-hospital mortality
between patients with dermatomyositis and controls. All
analyses were weighted to account for the survey sam-
pling procedure and to produce representative national
estimates. We developed univariate and multivariate
logistic regression models to estimate the odds of in-
hospital mortality by comparing dermatomyositis
patients with CVD to controls with CVD as well as der-
matomyositis patients with or without CVD.
Covariates
Covariates for multivariate analysis included important
clinical risk factors such as age, gender, type of admis-
sion (elective versus non-elective), and the Charlson
comorbidity index [11], which reflects 1-year mortality
due to comorbidities (scale of 0 to 37), to account for
concomitant illnesses [12]. The Charlson index is a pre-
diction index that includes the following diagnoses: MI,
congestive heart failure, peripheral vascular disease,
dementia, chronic pulmonary disease, connective tissue
disease, ulcer disease, mild liver disease, diabetes, renal
disease, non-metastatic solid tumor, leukemia, lym-
phoma, myeloma, metastatic tumor, or AIDS. We also
adjusted for the number of concurrent CVD diagnoses
in order to control for possible differences in reporting
accuracy. All analyses were performed by using the SVY
suite of SAS 9 (SAS Inc., Cary, NC, USA).
Results
Description of the study sample
A total of 10,156 hospitalizations were recorded in the
database, representing 50,323 hospitalizations of patients
with dermatomyositis in the US between 1993 and 2007.
Baseline characteristics are shown in Table 1. Half of
these admissions occurred in teaching hospitals, 39% in
urban hospitals, and 11% in rural hospitals. The mean
Linos et al. Arthritis Research & Therapy 2013, 15:R7
http://arthritis-research.com/content/15/1/R7
Page 2 of 5
age of patients was 58 years, and 73% of patients were
female. Approximately half of all hospitalized patients
with dermatomyositis were white, 12% were black, 8%
were Hispanic, and 4% were other. The mean length of
hospitalization was 8 days. The mean Charlson comor-
bidity index in our overall dermatomyositis patient
group was 1.4.
The most frequent primary discharge diagnoses in
hospitalizations of patients with dermatomyositis were
pneumonia and acute respiratory failure, congestive
heart failure, coronary atherosclerosis, sepsis, cellulitis,
and urinary tract infection. Of all dermatomyositis hos-
pitalizations, one fifth were associated with a concurrent
atherosclerotic cardiovascular diagnosis or procedure,
which was similar to the control group (Table 1). The
most common cardiovascular diagnosis in this group of
patients was congestive heart failure (12% of dermato-
myositis hospitalizations) followed by MI (4.4% of der-
matomyositis hospitalizations).
The overall in-hospital mortality in our dermatomyo-
sitis patient group was 5.7% over the study period. The
most frequent primary diagnoses in dermatomyositis
patients who died in the hospital were pneumonia
(including aspiration pneumonia), acute respiratory fail-
ure, sepsis, and congestive heart failure. Dermatomyosi-
tis patients with any of the specified atherosclerotic
cardiovascular diagnoses or procedures were twice as
likely to die during the inpatient stay compared with
dermatomyositis patients who did not have a concurrent
atherosclerotic cardiovascular diagnosis or procedure
(odds ratio (OR) = 2.0, 95% confidence interval (CI) 1.7
to 2.5, P < 0.0001) (Table 2). The highest odds of death
were noted for patients with congestive heart failure
(OR = 2.3, 95% CI 1.9 to 2.8, P < 0.001). The odds of
death were about twofold higher for hospitalized
patients with dermatomyositis and CVD compared with
hospitalized age- and gender-matched control patients
with CVD, and this finding persisted after adjustment
for comorbidities, admission type, and number of cardi-
ovascular diagnoses/procedures (OR = 1.98, 95% CI 1.57
to 2.48) (Table 3).
Discussion
In this large US-based hospitalization database, approxi-
mately one fifth of hospitalizations in patients with der-
matomyositis were associated with an atherosclerotic
cardiovascular diagnosis or procedure. Congestive heart
failure and coronary atherosclerosis were the second
and third most frequent primary diagnoses associated
with dermatomyositis hospitalizations, respectively, and
among the 10 most frequent primary diagnoses asso-
ciated with dermatomyositis patients who died in the
hospital. Patients with dermatomyositis and athero-
sclerotic CVD were almost twice as likely to die in hos-
pital than age- and gender-matched controls with
similar CVDs, even after adjustment for comorbidities,
emergency admission, and number of cardiovascular
diagnoses/procedures. In addition, dermatomyositis
patients with CVD were twice as likely to die compared
with patients with dermatomyositis and no CVD. This
suggests an additive effect of CVD and dermatomyositis
on risk of death. In addition to helping clinicians with
inpatient prognostication, this finding raises important
clinical questions about the possible need for more
aggressive cardiovascular risk factor assessment and
Table 1 Characteristics of patients and controls




Total number in sample 10,156 76,440
Weighted number (to US
population)
50,323 376,744
Mean age, years 58.3 58.5








1 (lowest category) 19.7 28.2
2 22.4 23.8
3 23.7 22.3




Urban, non-teaching 39.3 43.5
Urban, teaching 49.1 45.0
Mean length of hospitalization, days 8.0 5.1








Angina pectoris 1.2 1.3
Angina (either) 2.5 2.8
Congestive heart failure 11.8 9.9
Coronary artery bypass graft 0.4 0.01




Charlson comorbidity index 1.4 1.2
Overall in-hospital death rate per
1,000
56.5 24.0
aControls were matched for age and gender. MI, myocardial infarction.
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monitoring in dermatomyositis outpatients in order to
prevent hospitalization and death related to CVD.
Inflammatory myopathies have been linked to cardio-
vascular risk factors, including diabetes, hypertension,
and ischemic heart disease. In a recent study, the preva-
lence of hypertension and diabetes in these patients was
far higher than in the general population (62% and 29%
compared with 9% and 4%, respectively) [9]. Another
study found that the incidence of acute MI and cerebro-
vascular accident was higher in patients with dermato-
myositis and polymyositis than in age- and gender-
matched controls. In that study, the presence of hyper-
tension and hyperlipidemia increased the risk of arterial
events whereas the use of non-steroid immunomodula-
tors decreased the risk [10]. Although we were not able
to examine detailed risk factor profiles in individual
patients in this study, it is possible that hypertension
and diabetes may be appropriate targets for screening
and early intervention in patients with dermatomyositis.
Future studies evaluating the potential benefit of more
intense glucose and blood pressure monitoring in the
outpatient setting in this population would be helpful.
The risk of statins in patients with inflammatory myopa-
thies may complicate the treatment of hyperlipidemia;
however, screening and treatment with lifestyle changes
and non-statin medications may also be warranted in
this population.
The increased mortality observed in patients with both
dermatomyositis and atherosclerotic CVD compared
with inpatients with only one of those diagnoses is
significant for clinical prognostication. Our findings are
consistent with those of a prior retrospective cohort
study of 370 patients with inflammatory myositis (der-
matomyositis and polymyositis) indicating that CVD
accounts for most of the excess mortality seen in these
patients. In that study, the relative risk of death compar-
ing patients with ischemic heart disease to those without
was 2.97 (95% CI 1.65 to 5.28) [13]. Our findings are
also consistent with those of other studies showing that
cardiovascular involvement contributes to a significant
proportion of mortality in patients with dermatomyositis
[14,15].
Strengths of this study include the very large numbers
of cases included for such a rare disease as well as the
specific focus on patients with dermatomyositis. The
pathophysiology of dermatomyositis likely differs from
that of other inflammatory myopathies, such as poly-
myositis and inclusion body myositis, as illustrated by
differences in clinical expression, muscle biopsy findings,
and gene expression analyses. Therefore, dermatomyo-
sitis may represent a subgroup of inflammatory
myopathies with a particular risk associated with athero-
sclerotic CVD.
Limitations of this study include the cross-sectional
design, which cannot assess temporal relationships
between dermatomyositis and cardiovascular diagnoses.
Furthermore, this study relied on ICD-9 codes for the
definition of dermatomyositis, and this could have led to
misclassification. However, we recently found that the
ICD-9 code of 710.3 was 70% accurate in identifying
cases of dermatomyositis that fulfill Bohan and Peter
criteria for at least probable disease [11]. We also
attempted to reduce this misclassification by excluding
patients who had an additional concurrent rheumatolo-
gic diagnosis. Because the unit of analysis was hospital
discharge and not the individual patient, it is possible
that some patients would have been included more than
once if they had multiple hospitalizations. Because eth-
nicity is not reported by all states, we did not adjust our
analyses for race since the proportion of missing data
for this covariate was high (23%). The major limitation
of this study is that this is an administrative database
and so it is not possible to evaluate all possible variables.
For example, this dataset does not have information on
smoking status, medications, or laboratory measures of
inflammation that would inform potential mechanisms.
Finally, since our study used a hospitalization database,
these results may not be generalizable to all dermato-
myositis patients who are typically managed in the out-
patient setting.
Conclusions
One fifth of all hospitalizations for dermatomyositis
have an associated atherosclerotic cardiovascular
Table 2 Odds ratio for death, comparing patients with
dermatomyositis and cardiovascular disease diagnoses
with dermatomyositis patients without cardiovascular
disease
Cardiovascular diagnoses Odds ratio (95% CI) P value
Any cardiovascular diagnosis 2.04 (1.71-2.45) < 0.001
Myocardial infarction 1.57 (1.11-2.22) 0.01
Angina 0.34 (0.14-0.83) 0.02
Congestive heart failure 2.28 (1.85-2.80) < 0.001
Coronary artery bypass grafting - -
Coronary catheterization 0.51 (0.26-1.01) 0.053
Percutaneous angioplasty 0.47 (0.12-1.94) 0.30
CI, confidence interval.
Table 3 Odds ratio for in-hospital death, comparing
patients with dermatomyositis and cardiovascular
disease with controls with cardiovascular disease
Model Odds ratio (95% CI) P value
Univariate modela 2.11 (1.80-2.48) < 0.001
Multivariate modelb 1.98 (1.57-2.48) < 0.001
aAdjusted for age and gender only; badjusted for age, gender, Charlson
comorbidity index, number of diagnoses (to control for severity of admission),
and type of admission (elective versus emergency). CI, confidence interval.
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diagnosis or procedure. Patients with both dermatomyo-
sitis and CVD have double the risk of in-hospital death
compared with hospitalized age- and gender-matched
controls with CVD and compared with hospitalized der-
matomyositis patients without CVD. Identification of
these groups is important for both prognostic purposes
and clinical care. Further prospective studies are neces-
sary to confirm our findings and to analyze the relative
contribution of disease activity and treatments on the
increased mortality associated with CVD in patients
with dermatomyositis. Future studies are also needed to
assess whether systematic outpatient screening for and
treatment of cardiovascular risk factors, including dia-
betes, hyperlipidemia, or hypertension, may be beneficial
in reducing cardiovascular mortality in patients with
dermatomyositis.
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